 Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.773.875 G07.690.936.500
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 21 | 21 | | 1995 | 0 | 21 | 21 | | 1996 | 0 | 20 | 20 | | 1997 | 0 | 28 | 28 | | 1998 | 0 | 17 | 17 | | 1999 | 0 | 24 | 24 | | 2000 | 0 | 33 | 33 | | 2001 | 0 | 35 | 35 | | 2002 | 0 | 26 | 26 | | 2003 | 0 | 64 | 64 | | 2004 | 0 | 66 | 66 | | 2005 | 0 | 61 | 61 | | 2006 | 0 | 57 | 57 | | 2007 | 0 | 66 | 66 | | 2008 | 0 | 86 | 86 | | 2009 | 0 | 61 | 61 | | 2010 | 0 | 65 | 65 | | 2011 | 0 | 57 | 57 | | 2012 | 0 | 63 | 63 | | 2013 | 0 | 51 | 51 | | 2014 | 0 | 73 | 73 | | 2015 | 0 | 62 | 62 | | 2016 | 0 | 54 | 54 | | 2017 | 1 | 60 | 61 | | 2018 | 0 | 44 | 44 | | 2019 | 0 | 41 | 41 | | 2020 | 0 | 32 | 32 | | 2021 | 0 | 17 | 17 | | 2022 | 0 | 5 | 5 | | 2023 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Brown KT, Levis SC, O'Neill CE, Levy C, Rice KC, Watkins LR, Bachtell RK. Toll-like receptor 4 antagonists reduce cocaine-primed reinstatement of drug seeking. Psychopharmacology (Berl). 2023 Jul; 240(7):1587-1600.
-
Bookman J, Rocks M, Noh K, Ayalon O, Hacquebord J, Catalano L, Glickel S. Determining the Optimal Dosage of Corticosteroid Injection in Trigger Finger. Hand (N Y). 2024 Oct; 19(7):1080-1083.
-
Kim R, Leal AD, Parikh A, Ryan DP, Wang S, Bahamon B, Gupta N, Moss A, Pye J, Miao H, Inguilizian H, Cleary JM. A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol. 2023 04; 91(4):291-300.
-
Sura AA, Sun Y, Reddy AK, Rathinam SR, Gonzales JA, Thundikandy R, Vedhanayaki R, Kanakath A, Murugan B, Doan TA, Lim LL, Suhler EB, Al-Dhibi HA, Acharya NR. Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial. Ocul Immunol Inflamm. 2024 Aug; 32(6):955-960.
-
Ma WW, Li JJ, Azad NS, Lam ET, Diamond JR, Dy GK, Opyrchal M, Zhi J, Kramer D, Chan WK, Cutler D, Kwan R, Adjei AA, Jimeno A. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. Cancer Chemother Pharmacol. 2022 07; 90(1):7-17.
-
Diamond JR, Boni V, Lim E, Nowakowski G, Cordoba R, Morillo D, Valencia R, Genvresse I, Merz C, Boix O, Frigault MM, Greer JM, Hamdy AM, Huang X, Izumi R, Wong H, Moreno V. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clin Cancer Res. 2022 04 01; 28(7):1285-1293.
-
Rudolph J, Jung K, Luger K. Inhibitors of PARP: Number crunching and structure gazing. Proc Natl Acad Sci U S A. 2022 03 15; 119(11):e2121979119.
-
Auchus RJ, Sarafoglou K, Fechner PY, Vogiatzi MG, Imel EA, Davis SM, Giri N, Sturgeon J, Roberts E, Chan JL, Farber RH. Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2022 02 17; 107(3):801-812.
-
?akir I, Hadley CK, Pan PL, Bagchi RA, Ghamari-Langroudi M, Porter DT, Wang Q, Litt MJ, Jana S, Hagen S, Lee P, White A, Lin JD, McKinsey TA, Cone RD. Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity. Nat Metab. 2022 01; 4(1):44-59.
-
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|